PPAR might not be permissive to ligand activation in prostate cancer cells. Association of PPAR with repressing factors or post-translational modifications in PPAR protein could explain the lack of effect of PPAR ligands in a recent randomized clinical trial. Using cells and prostate cancer xenograft mice models we demonstrate in this study that a combination treatment 5 using the PPAR agonist pioglitazone and the HDAC inhibitor valproic acid is more efficient in inhibiting prostate tumor growth than each individual therapy. We show that the combination treatment impairs bone-invasive potential of prostate cancer cells in mice. In addition, we demonstrate that expression of E-cadherin, a protein involved in the control of cell migration and invasion is highly up-regulated in the presence of valproic acid and pioglitazone. We show that 10 E-cadherin expression responds only to the combination treatment, and not to single PPAR agonists, defining a new class of PPAR target genes. These results open up new therapeutical perspectives in the treatment of prostate cancer.
Introduction
Prostate cancer is the most common form of cancer in men, and the second leading cause of 15 cancer deaths. Tumor growth is originally androgen dependent. Androgens exert their effects through activation of the Androgen receptor (AR), a member of the hormone nuclear receptor superfamily. In the mature prostatic gland, AR regulates the expression of genes involved in cell division and proliferation of the epithelial cells (26). AR is also involved in several other aspects of prostate cellular metabolism, including lipid biosynthesis and controls the production of 20 specialized secretory proteins with prostate-restricted expression such as with prostate-specific antigen (26). When prostate cancer is still hormone-dependent, androgen ablation therapy causes regression of the tumor (18), likely through inactivation of the transcription of the AR target genes. However, the durability of this response is inadequate and many men develop recurrent androgen-independent prostate cancer, which has a very poor prognosis (see (11) for review). 25
Other nuclear receptors or locally produced factors that interact with nuclear receptors are likely involved in cell proliferation, differentiation, and apoptosis in the prostate. The peroxisome proliferator-activated receptor gamma (PPAR ) is one of such factors. PPAR is another member of the hormone nuclear receptor superfamily. As for most of the other members of this family its activity is regulated by ligands. Prostaglandin J2 and the anti-diabetic drugs thiazolidinediones 30 have been determined as natural and synthetic ligands of PPAR respectively (for review see (9)).
PPAR is highly expressed in the adipose tissue and is required for its development through regulation of the expression of adipocyte-specific genes, such as lipoprotein lipase (LPL), or the fatty acid transport protein aP2. In addition to adipose tissue, PPAR is expressed in several other tissues, including gut, macrophages, lung, bladder, breast, or prostate, although its function in 35 these tissues remains to be elucidated. Interestingly, PPAR has been shown to be over-expressed in prostate cancer (15) . Whereas the physiological function of PPAR in normal epithelial cells is largely unknown, PPAR activation was reported to inhibit the proliferation of prostate carcinoma cells (4, 21, 25, 34), and also other cancer lineages (7). These observations suggest that induction of differentiation by activation of PPAR may represent a promising novel 40 therapeutic approach for cancer, as already demonstrated in xenograft models of prostate (21). In addition, treatment of patients with advanced prostate cancer with the PPAR agonist troglitazone resulted in the stabilization of prostate-specific antigen levels (25). In contrast, in a large scale placebo-controlled randomized clinical trial, no effects were observed in the PSA doubling time of prostate cancer patients (35). These results suggest that PPAR is not permissive for activation 45 by ligands in these prostate cancer patients. One interesting hypothesis is that some factors could prevent activation of PPAR by its ligands in cancer cells. One of such factors is histone deacetylases (HDAC). Deacetylation of histones has been correlated with a transcriptionally silent state of chromatin. Inhibition of HDAC activity by natural or synthetic compounds results in the reversion of the phenotype of tumoral cells into normal cells, or apoptosis of cancer cells 50 (22) . Although the precise mechanisms have not been yet elucidated, HDAC inhibition results in the selective induction of endogenous genes that play roles either in differentiation or cell cycle arrest. We demonstrated in previous studies that HDAC3 is complexed with PPAR in the promoters of PPAR target genes, and that this association results in the repression of these target genes. HDAC inhibitors, such as valproic acid or sodium butyrate (NaBu) had a synergistic 55 effect with TZDs in the activation of PPAR-target genes (8). Therefore, HDAC inhibition could render PPAR permissive to activation by its ligands. We show in this study that a combination treatment of HDAC inhibitors and PPAR agonists results in the arrest of proliferation, increases apoptosis and decreases the invasion potential of prostate cancer cells both in vitro and in vivo.
Furthermore we show that PPAR agonists increase the expression of E-cadherin mRNA only in 60 the presence of HDAC inhibitors, which define a new class of PPAR target genes.
Materials and Methods

Materials and oligonucleotides. Pioglitazone was a kind gift of Takeda Pharmaceuticals
Industries (Osaka, Japan). Rosiglitazone was purchased from VWR-Calbiochem (Fontenay sous 65 Bois, France). All chemicals, except if stated otherwise, were purchased from Sigma (St Louis, MO, USA). Anti-CDK4 (C-22), anti-PPAR (H-100 for ChIP, N-20 for immunohistochemistry), anti-HDAC-3 (H-99) and anti-PCNA (PC-10) antibodies were from Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-acetyl H4 (Lys 12) and anti-Phospho-Rb (ser 807/811) were from Cell Signaling (Beverly, MA, USA), anti-p21 (Ab-1) was from EMD Biosciences (Darmstadt, 70 Germany), anti-p27 was from NeoMarkers (Fremont, CA, USA) and anti-BrdU and anti Ecadherin (NCH-38) antibodies were from Dako (Glostrup, Denmark). The oligonucleotide sequences used for various experiments in this manuscript are available upon request. 5.10 -6 M, valproic acid (1.5 mM for PC3, 0.75mM for DU145 and 0.375mM for LNCaP) or both pioglitazone and valproic acid. Tansient transfections were performed as described previously (2) 80 and luciferase activity measurements were normalized for ß-galactosidase activity to correct for differences in transfection efficiency. Graph values represent the mean of three independent experiments. For siRNA experiments, smart-pool siRNAs against HDAC3 (Dharmacon, Lafayette, CO, USA) were transfected in PC3 cells using DharmaFECT TM 2 (Dharmacon) following manufacturer's instructions. After 24 h, cells were treated as described above and 85 incubated for 24 h. Effects of the siRNA on HDAC3 mRNA and protein levels are illustrated in figure 7B and C, respectively.
Apoptosis and BrdU assays, flow cytometry analysis and phospho-pRb detection.
Proliferating LNCaP, DU145 and PC3 cells were incubated for 48 h with the different treatments as described above. For all immunofluorescence experiments, cells were grown on coverslips. 90 Apoptotic cells were detected using Alexa 568 conjugated-annexin V labeling following manufacturer's instructions (Roche, Basel, Switzerland). For BrdU incorporation, cells were incubated 4h for PC3 and DU145 and 16h for LNCaP in the presence of 100 µM BrdU, harvested and fixed with methanol. An additional treatment of the cells with 1.5 N HCl for 10 min was performed. Cells were then incubated with the anti-BrdU antibody (dilution 1:100) for 16 h at 95 4°C, and BrdU staining was revealed using a Texas-red-conjugated anti-mouse IgG. For phospho-pRb immunofluorescence detection, PC3 cells were harvested after 48 h treatment, fixed in methanol for 10 min at 4°C, and incubated for 16 h at 4°C with the anti-phospho-pRb antibody (dilution 1:50), and phospho-pRb staining was revealed using a Texas-red-conjugated anti-rabbit IgG. At least 500 cells were counted. For FACS analysis, cells were harvested, fixed with EtOH 100 70%, and DNA was labeled with propidium iodide. Cells were sorted by FACS analysis (Coulter Electronics, Hialeah, FL, USA) and cell cycle profiles were determined using the ModFit software (Becton Dickinson, San Diego, CA, USA).
RNA extraction, RT-PCR and Q-PCR.
RNA extraction and reverse transcription were performed as described (3). Q-PCR was carried out using a LightCycler and the DNA double 105 strand specific SYBR Green I dye for detection (Roche). Q-PCR was performed using genespecific oligonucleotides and results were then normalized to RS9 levels.
Protein extracts and western blot analysis. Protein extracts and sodium dodecyl sulfate (SDS)-
polyacrylamide gel electrophoresis (PAGE), electrotranfer and immunoblotting were performed as described (31). 110
Kinase assays. CDK4 immunoprecipitation and kinase assays were performed exactly as previously described (1).
In vivo murine models of prostate cancer. Male Rj:NMRI-nu (nu/nu) (Janvier, Le Genest-StIsle, France) and CD17-SCID/bg (Harlan, Gannat, France) mice were maintained according to European Union guidelines for use of laboratory animals. In vivo experiments were performed in 115 compliance with the French guidelines for experimental animal studies (Agreement No. B-34-172-27). For in vivo proliferation studies, 3.10 6 luminescent PC3 cells were laterally injected subcutaneously (s.c.) in nude mice at 6 weeks of age. 5 days after s.c. injection, cohorts (10 mice/group) were orally administrated the vehicule (0.5% carboxy methyl cellulose (CMC)), pioglitazone (30 mg/kg/d in 0.5% CMC), valproic acid (150 mg/kg/d in 0.5% CMC) or both 120 compounds for a period of 4 weeks. Tumor progression was determined by measuring the volume of the tumor with a caliper. Tumor tissues were collected, weighted, fixed in 4% phosphatebuffered formalin and embedded in paraffin for immunohistological analyses. For in vivo boneinvasion studies, subconfluent monolayers of luminescent PC3 cells were detached by trypsinization, washed, and resuspended in PBS to the working concentration of 5 x 10 5 cells/10 125 µl. All tibiae injections were performed on SCID mice (10 mice/group) anesthetized with pentobarbital (50 mg/Kg). The proximal end of the left tibiae bones was exposed surgically in a flex position and 10 µl of PBS containing tumor cells were injected into the bone marrow space with a 26-gauge needle. Mice were treated 7 days after intra-tibiae injection with vehicle (0.5% CMC), pioglitazone (30 mg/kg/d in 0.5% CMC), valproic acid (300 mg/kg/d in 0.5% CMC) or 130 both compounds for a period of 4 weeks and monitored weekly for tumor growth kinetic using bioluminescence imaging with the NightOWL LB981 CCD camera (Berthold Technologies, Bad Wildbad, Germany) and WinLight software (Berthold Technologies). Left and right legs were harvested, and fixed in 4% phosphate-buffered formalin, X-rays of the legs were taken and invasion potential was scored by 4 blind comparisons of X-ray radiographs. Scores ranged from 0 135 (no invasion) to 4 (high degree of invasion). For both xenograft mouse models, tumor formation was verified one day before starting treatment using bioluminescence imaging. No failure rate for tumor initiation was observed and tumor growth was occurring at the same rate.
Immunohistochemistry (IHC) and histology. IHC was performed as described previously (2) . Briefly, after antigen retrieval, 5µm formalin-fixed luminescent PC3 tumor sections were 140 incubated with the anti-PCNA (dilution 1:500), anti-p21 (dilution 1:20) and anti-E-cadherin (dilution 1:25) antibodies and the LandMark™ Prostate Tissue MicroArray (Ambion, Austin, TX, USA) containing 5µm formalin-fixed paraffin-embedded human normal and tumor prostate sections were incubated with the anti-PPAR (dilution 1:25) or the anti-acetyl H4 antibodies (dilution 1:25). Immunostainings were revealed using peroxydase-conjugated anti-mouse (for 145 PCNA, p21 and E-cadherin, Jackson Immunoresearch, Cambridgeshire, UK), anti-goat (for PPAR , Jackson Immunoresearch) or anti-rabbit (for acetylated H4, Jackson Immunoresearch) secondary antibodies and the DAB chromogen (DAKO) as a substrate. Sections were counterstained with haematoxylin. For E-cadherin, immunofluorescence staining was revealed using a Texas-red-conjugated anti-mouse secondary antibody. Negative controls using mouse, 150 rabbit or goat IgGs were performed and no staining was observed in these conditions. Trained pathologists analyzed the PPAR , acetyl H4 and E-cadherin stainings. Immunohistochemical quantification was based on two parameters, the intensity of the staining and the percentage of cells positively stained, leading to 4 groups : 0, no staining; 1, weak positive staining; 2, moderate staining and 3, strong staining. 155
Invasion assay. The Boyden chamber migration assay was performed as described previously (12) . Briefly, polycarbonate filters (12 µm pore) were coated with 60 µg of Matrigel (Becton Dickinson). Cells were harvested in medium containing 3% FCS and ligands (vehicle, 5 µM pioglitazone, 1.5 mM valproic acid, or both) and added to the top chamber (1.10 6 cells per chamber). Medium supplemented with 10% FCS and ligands was used in the bottom 160 compartment as a chemo-attractant. To correct for proliferation and/or cell death due to our treatments, cells were cultured in parallel in 12-wells plates in medium containing 3% FCS and ligands (control plate corresponding to total cells). Chambers and plates were incubated for 48 h at 37°C and cells that had traversed the Matrigel and spread on the bottom surface of the filter as well as cells from control plates were then quantified using 3(4,5-dimethyl-thiazol-2-yl)2,5-165 diphenol tetrazolium bromide and determination of OD 540 . Experiments were performed in triplicate, and results are expressed as percentage of invading cells relative to total control cells.
Electro mobility shift assays (EMSA). EMSA were performed as described previously (2, 10).
Briefly, in vitro translated PPAR and RXR were incubated for 15 min at 21°C in a total volume of 20 µl binding buffer [(10mM Tris-HCl (pH 7.9), 40 mM KCl, 10% glycerol, 0.05% 170 Nonidet P-40, 1mM DTT and 1 µg poly(dI:dC)] in the presence of 2 ng of a T4-PNK end labeled double-stranded oligonucleotide probe. For gel supershift assay, 2µg of IgG or PPAR antibody were added to the reaction. DNA-protein complexes were separated by electrophoresis on a 4% polyacrilamide gel in 0.25% TBE at 4°C and 10V/cm.
Cloning of the E-cadherin and aP2 promoters. The E-cadherin and aP2 promoters were cloned 175 using the BD Advantage GC Genomic polymerase mix (BD Biosciences Clontech, Palo Alto, CA, USA) and genomic DNA as a template. PCR amplifications were performed according to the manufacturer's instructions and cloned in the pGL3-basic vector (Promega Life Science, Madison, WI, USA). A deletion E-cadherin promoter mutant devoid of the PPRE was obtained by PCR using specific primers and cloned as described above. The different pGL3 promoter 180 constructs were sequenced and used in transient transfections.
Co-immunoprecipitation.
Immunoprecipitation assays were performed as previously described (8).
Chromatin immunoprecipitation (ChIP) and Re-ChIP. ChIP assays were performed as described previously (3) . Re-ChIP assays were performed as described (23). Briefly, proteins 185 from PC3 cells treated for 48 h with different ligands were formaldehyde cross-linked to DNA.
After lysis and DNA sonication, proteins were then immunoprecipitated using an anti-PPAR antibody. After washing, DNA-protein-complexes were subsequently eluted in 10mM DTT for 30 min at 37°C and re-immunoprecipitated using IgG (negative control) or anti-HDAC3 antibody. Cross-linking was then reversed by heating the samples at 65°C for 16 h. DNA was 190 then purified using Qiagen PCR purification kit (Qiagen, Courtaboeuf, France), and PCR amplification was performed using promoter-specific oligonuleotide primers. fig. 1A ). Most interestingly, the combination treatment of pioglitazone/valproic acid and rosiglitazone/valproic acid decreased the proliferation index to 1.5% ± 0.1 and 1.6 % ± 0.01, respectively. To further prove that the effect of the combination treatment was independent on the cell line, two androgen-independent prostate cancer cell lines, i.e. DU145 (AR -, Rb -, p53 215 mt) and PC3 (AR -, Rb wt, p53 -), were subjected to BrdU incorporation ( fig. 1B and C) . In To evaluate the in vivo effect of a combined therapy of pioglitazone and valproic acid on prostate 280 cancer development, we used an immuno-deficient mouse model in which luminescent PC3 cells were grafted sub-cutaneously, allowing us to follow tumor initiation and progression using bioluminescent imaging. We observed no failure in tumor initiation, with 100% grafted cells giving rise to a tumor. No significant differences on tumor volume and mass were observed in mice treated with either pioglitazone or valproic acid, whereas a 40% decrease in tumor volume 285 and mass was observed in mice treated with the combination of pioglitazone and valproic acid, compared to mice treated with vehicle ( fig. 3A-B) . Consistent with the inhibition of tumor growth, a decrease in cell proliferation in tumors of mice treated with the combination therapy was observed, compared to tumors of mice treated with vehicle, as measured by PCNA staining on histological sections of the tumors ( fig. 3C-D) . Consistent with the size of tumors ( fig. 3A-B) , 290 no effect on tumor cell proliferation was observed when each single agent (pioglitazone or 3A ; 41.9% ± 2.0 for control, 32.2% ± 8.6 for pioglitazone), whereas decreased invasion was observed when PC3 cells were treated with valproic acid (24.0% 310 ± 2.3). Strikingly, a synergistic effect in the inhibition of invasion was observed when a combination of pioglitazone and valproic acid was used (11.4% ± 3.1). These results suggested that the invasion potential of highly metastatic prostate cancer cells, in the presence of the combination treatment, was inhibited.
These data prompted us to study the effect of pioglitazone and valproic acid on the inhibition of 315 invasion in vivo. Prostate cancer cells preferentially invade bone. We therefore used a bone invasion model by intra-tibially injecting luminescent PC3 cells in immunodeficient mice. Mice were treated thereafter for 30 days with the combination therapy pioglitazone and valproic acid.
In vivo imaging techniques using a CCD camera facilitated the follow up of tumor initiation and growth in these animals by quantification of the luciferase signal after intraperitoneal luciferine 320 injection. As described for sub-cutaneous xenograft, no failure in tumor initiation was observed.
To characterize the in vivo bone invasion potential of our xenografted-PC3 cells, X-ray analysis of the legs were performed and bone destruction was scored from 0 (no destruction, thus no invasion) to 4 (high degree of bone destruction, demonstrating a high invasion potential, fig. 4B ).
X-ray analysis of treated mice showed preservation of bone structure and density, whereas 325 massive bone destruction was observed in non-treated mice ( fig. 4C) fig. 5E, lanes 1, 2 and 3) . These results suggested that the PPAR /RXRa heterodimer could regulate the expression of E-cadherin through direct 360 binding to its promoter.
To determine whether PPAR /RXR could activate the human E-cadherin promoter in vitro, COS cells were then co-transfected with a PPAR expression vector and with the full-length Ecadherin promoter containing the PPRE driving the expression of the luciferase gene or a deletion mutant devoid of this PPRE. No effect of pioglitazone on E-cadherin promoter activity was 365 observed in the presence of PPAR expression vectors, whereas valproic acid induced up to 3-fold E-cadherin promoter activity. Consistent with increased E-cadherin mRNA expression ( fig.   5A-B) , the combination of pioglitazone and valproic acid had synergistic effects and induced up to 5-fold the activity of the full length E-cadherin promoter in COS ( fig. 5F ). This synergistic effect was abrogated when the PPRE of the E-cadherin promoter was deleted ( fig. 5F ), 370
suggesting that PPAR was mediating the synergistic effects. The same results were obtained when PC3 cells were transiently transfected (data not shown). Interestingly, the E-cadherin gene contains a functional PPRE that is responsive to PPAR , but only in the presence of HDAC inhibitors.
375
E-cadherin is a new class of PPAR target genes responding only to the combination treatment.
To further elucidate the molecular mechanisms underlying this particular effect of PPAR on the expression of E-cadherin, we first tested the presence of the HDAC3 repressor protein in the PPAR complex in PC3 cells by co-immunoprecipitation studies. We first verified that our 380 treatments had no impact on PPAR and HDAC3 protein levels, as demonstrated by immunoblotting ( fig. 6A ). When protein extracts from PC3 cells were immunoprecipitated using an anti-HDAC3 antibody endogenous PPAR protein was associated to HDAC3 in the control, pioglitazone and valproic acid-treated cells, and was minimally detected in cells co-treated with pioglitazone and valproic acid ( fig. 6B ). To further prove that HDAC3 is associated with PPAR 385 and represses its transcriptional activity, chromatin immunoprecipitation studies of the Ecadherin promoter were performed. A 414 bp fragment of the human E-cadherin promoter containing the binding site of PPAR was amplified by PCR when anti-PPAR was used to immunoprecipitate chromatin from vehicle, pioglitazone, valproic acid and pioglitazone plus valproic acid-treated cells ( fig. 6C, PPRE and supplemental figure S1B ). Interestingly, a PCR 390 amplification product was observed when anti-HDAC3 was used to immunoprecipitate chromatin from either vehicle, pioglitazone, or valproic acid-treated cells, whereas no amplification was observed when immunoprecipitated chromatin from cells treated with the combination of pioglitazone and valproic acid was used as a template nor when non-specific IgGs were used to immunoprecipitate the chromatin (fig. 6C, PPRE and supplemental figure S1B) . Moreover, when 395 using an anti-acetylated histone H4 antibody, the E-cadherin promoter could be amplified in valproic acid and pioglitazone plus valproic acid treated cells indicating that, in these conditions, the E-cadherin promoter was activated ( fig. 6C , PPRE and supplemental figure S1B). Binding of PPAR and HDAC3 was specific to the PPAR binding site of the E-cadherin promoter, since no amplification of a promoter region located outside of the PPRE was observed ( fig. 6C , non 400 PPRE). However, when chromatin was immunoprecipitated using an anti-acetylated histone H4, we observed amplification of the region devoid of the PPRE after treatments of the cells with valproic acid and pioglitazone plus valproic acid, and to a much lesser extent with pioglitazone, suggesting that this region is also transcriptionally active ( fig. 6C, non PPRE) . To further prove the direct association of HDAC3 with PPAR on the E-cadherin promoter, we performed Re-405
ChIP experiments. After a first chromatin immunoprecipitation using an anti-PPAR antibody, we performed a second immunoprecipitation using an anti-HDAC3 antibody or non-specific IgGs. As observed for ChIP experiments, the same fragment of the human E-cadherin promoter was amplified by PCR when anti-HDAC3 was used to immunoprecipitate chromatin from vehicle, pioglitazone or valproic acid treated cells ( fig. 6D and supplemental figure S1C) , 410 demonstrating that HDAC3 forms a complex with PPAR in PC3 cells on the E-cadherin promoter even in the presence of valproic acid. No association of PPAR and HDAC3 to the Ecadherin promoter was observed when chromatin from cells treated with a combination of pioglitazone and valproic acid was used ( fig. 6D and supplemental figure S1C ).
Finally, we asked whether other known PPAR target genes, such as aP2 responded similar to E-415 cadherin to the treatments. In contrast to what observed for the E-cadherin gene, aP2 mRNA expression was induced more that 100-fold in PC3 cells treated with pioglitazone compared to cells treated with vehicle ( fig. 6E) . Surprisingly, only minor effects on aP2 mRNA expression were observed upon treatment with valproic acid (fig. 6E) . Furthermore, combination treatment of pioglitazone and valproic acid induced aP2 mRNA expression at similar levels as observed for 420 pioglitazone treatment alone ( fig. 6E ). These results suggested that PPAR differentially regulated transcription in the context of the E-cadherin or the aP2 genes. Transient transfection assays in COS and PC3 (data not shown) cells using the aP2 luciferase-based promoter construct were consistent with this hypothesis. As observed for the aP2 mRNA expression, pioglitazone induced the aP2 promoter activity, whereas no effect on luciferase activity was observed upon 425 valproic acid treatment ( fig. 6F ). Moreover, no additive effect of the association of pioglitazone and valproic acid on luciferase activity was observed for this promoter ( fig. 6F ). To elucidate the molecular mechanism underlying the observed effects, Re-ChIP experiments were performed on the aP2 gene as described above. A 567 bp fragment of the human aP2 promoter containing the PPRE was amplified by PCR when anti-HDAC3 was used to re-immunoprecipitate PPAR -430 immunoprecipitated chromatin from vehicle-treated PC3 cells ( fig. 6G and supplemental figure   S1D ). In contrast to E-cadherin gene promoter, HDAC3 was not present on the aP2 promoter of PC3 cells treated with pioglitazone, valproic acid or both suggesting that HDAC3 is not associated with PPAR in these conditions on the aP2 promoter ( fig. 6G and supplemental figure   S1D ). Altogether, our data suggest that the E-cadherin and aP2 genes are differentially 435 transcriptionally regulated by PPAR . Regulation of E-cadherin expression by PPAR requires inhibition of HDACs regardless of the presence of PPAR ligands, whereas in the context of the aP2 promoter, PPAR ligands are sufficient to induce expression.
HDAC3 mediates repressive effects on PPAR -mediated E-cadherin promoter activity. 440
We observed by ChIP experiments that HDAC3 is recruited on the E-cadherin promoter upon pioglitazone or valproic acid treatment. To further prove that HDAC3 mediates repressive effects on the E-cadherin promoter, we first evaluated the effect of the transient over-expression of HDAC3 on PPAR -mediated E-cadherin promoter activity. COS cells were transiently cotransfected with the PPAR expression vector, the full-length E-cadherin promoter driving the 445 expression of the luciferase gene and increasing amount of the HDAC3 expression vector ( fig.   7A ). The combination of pioglitazone and valproic acid induced the E-cadherin promoter activity in the absence of HDAC3 ( fig. 5E and 7A) . Interestingly, when increasing amount of HDAC3 were co-transfected with PPAR , a strong decrease in the E-cadherin promoter activity was 7B and C, respectively) . siRNA-mediated HDAC3 knock-down increased endogenous Ecadherin mRNA expression in PC3 treated with pioglitazone (2-fold induction, fig. 7D ), whereas 455 no effect of pioglitazone was observed with the control siRNA ( fig. 7D ). These results suggest that HDAC3 represses PPAR transcriptional activity on the E-cadherin gene in PC3 cells upon pioglitazone treatment.
E-cadherin expression is decreased whereas PPAR expression and deacetylated histone H4 460
are increased in human prostate cancer.
One important requirement in order to insure a successful therapy using a combination of PPAR agonists and HDAC inhibitors is that PPAR is expressed in prostate cancer, and that histones are deacetylated. Consistent with previous studies (32) we found by IHC studies that PPAR was mainly not expressed in normal prostate ( fig. 8A) This was demonstrated in a study showing that sustained activation of PPAR by the new PPAR activator R-etodolac required the presence of HER2 inhibitors, suggesting that the HER2 pathway, likely through MAPK phosphorylation of PPAR , abrogated the effects of PPAR activity through degradation of this nuclear receptor (14) . In this scenario, PPAR ligands cannot activate PPAR as a result of its degradation. We show in our study that, similar to what is 515 observed for the HER2-PPAR axis, inhibition of HDAC activity is required to achieve maximal PPAR activation in prostate cancer cells. We have previously shown that PPAR is part of a HDAC3-containing repressor complex in the presence of PPAR ligands, and we characterized a PPAR -HDAC3 direct interaction (8). We believe that in prostate cancer cells HDACs are fully active ( fig. 8) , and therefore PPAR activity is repressed in these cells even in the presence of 520 ligands. HDAC inhibition has been shown to result in decreased proliferation of several cancer cells (22). We found that histone H4 acetylation levels were decreased in prostate cancer tumors, although the precise correlation between histone acetylation level and tumor stage is more complex (33).
We found that PPAR might control tumor growth at two different levels. First, this nuclear 525 receptor might exert anti-proliferative effects through regulation of the expression of cell cycle regulators. This is consistent with previous studies showing decreased expression of cyclin D1 upon PPAR agonists treatment in cancer cell lines (38). Second, we found that the combination treatment abrogated the invasive potential of prostate cancer cells. It is known that E-cadherin is one of the major factors that inhibit metastasis and invasion of prostate cancer cells through 530 maintenance of the adherens junctions important for epithelial cell-cell adhesion, and inhibition of epithelial-to-mesenchymal transition (EMT), which is a required event in cancer progression.
Downregulation of E-cadherin expression contributes to certain aspects of oncogenesis (5), and it
has been observed in 50% of prostate cancers (24, 36, 37). We consistently found increased expression of E-cadherin in PC3 cells treated with the combination therapy. Furthermore, we 535
show that E-cadherin is a bona fide PPAR target gene. In contrast to classical PPAR target genes, regulation of E-cadherin expression in response to PPAR ligands both at the promoter and RNA levels requires, however, the presence of HDAC inhibitors to fully achieve maximal stimulation. This is consistent with our hypothesis that PPAR is not permissive for activation by ligands when complexed with HDACs. This is demonstrated by our ChIP experiments, which 540
show that despite PPAR being bound to the promoter of the E-cadherin gene in the presence of ligand, the promoter is not active, as shown by transient expression experiments and E-cadherin mRNA quantification. The lack of activity is most likely the result of the presence of HDAC3 in this PPAR complex on the PPAR binding site of the E-cadherin promoter, a phenomenon that we cannot explain and are currently investigating. However, in the presence of HDAC inhibitors 545 and PPAR ligands HDAC3 is absent from the PPAR complex in the E-cadherin gene promoter, and consequently the promoter is active, as suggested by the activity of the E-cadherin promoter.
The finding that E-cadherin expression responds to PPAR agonists only in the presence of HDAC inhibitors defines a new class of PPAR target genes.
In support of this we show that classical PPAR target genes, such as aP2 responded to PPAR 550 with a 6-fold activation in the absence of HDAC inhibitors ( fig. 6 ). This suggests that the sensitivity of PPAR repression to HDACs is different depending on the context of the promoter of the PPAR -target gene. We can conclude from our results that a combination therapy using PPAR agonists and HDAC inhibitors might be considered for the treatment of prostate cancer. G, Re-ChIP assays demonstrating interaction between HDAC3 and PPAR on the aP2 promoter.
Chromatin was prepared and subjected to the Re-ChIP procedure as described in D .
Immunoprecipitates were analyzed using primers specific for the aP2 promoter. 810 
